Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China

BACKGROUND: Pegylated interferon (PEG-IFN) alfa-2b is recommended for chronic hepatitis B (CHB). We aimed to investigate the sustainability of off-treatment responses among Chinese HBeAg-positive CHB patients treated with PEG-IFN alfa-2b from a randomized trial. METHODS: Eligible Chinese patients (n...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Jian, Ding, Huiguo, Chen, Guofeng, Wang, Guiqiang, Wei, Lai, Zhang, Jiming, Xie, Qing, Wan, Mobin, Tang, Hong, Chen, Shijun, Gao, Zhiliang, Wang, Yuming, Zhang, Dazhi, Huang, Wenxiang, Sheng, Jifang, Ning, Qin, Yang, Dongliang, Lu, Jian, Pan, Chen, Yang, Yuxiu, Wang, Jue, Sun, Chuanzhen, Wang, Qixin, Hou, Jinlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498535/
https://www.ncbi.nlm.nih.gov/pubmed/31046700
http://dx.doi.org/10.1186/s12876-019-0981-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498535/
https://www.ncbi.nlm.nih.gov/pubmed/31046700
http://dx.doi.org/10.1186/s12876-019-0981-5

Ejemplares similares